Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.61 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.49 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049391 | 0.88 | ERCC1 (0.64) | ERCC1ERCC4MEP1AMEP1BROCK2 | |
| SCHEMBL17549817 | 0.85 | CYP3A4 (0.68) | CYP3A4CYP2C19L3MBTL1EPHX2 | |
| SCHEMBL26051518 | 0.83 | SMN1; SMN2 (0.51) | ERCC1ERCC4MEP1AMEP1BROCK2 | |
| SCHEMBL28822091 | 0.82 | ERCC1 (0.64) | ERCC1ERCC4MEP1AMEP1BROCK2 | |
| SCHEMBL19002484 | 0.82 | CYP3A4 (0.56) | CYP3A4CYP2C19L3MBTL1EPHX2 | |
| SCHEMBL38654611 | 0.82 | ERCC1 (0.59) | ERCC1ERCC4MEP1AMEP1BROCK2 | |
| SCHEMBL8645386 | 0.82 | ERCC1 (0.59) | ERCC1ERCC4MEP1AMEP1BROCK2 | |
| SCHEMBL24943229 | 0.82 | ERCC1 (0.60) | ERCC1ERCC4CYP3A4CYP2C19MEP1A | |
| SCHEMBL19002510 | 0.82 | ERCC1 (0.60) | ERCC1ERCC4MEP1AMEP1BROCK2 | |
| SCHEMBL3461756 | 0.80 | ERCC1 (0.60) | ERCC1ERCC4CYP2C19MEP1AMEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | ERCC1 3013/4885ERCC4 2678/4885CYP3A4 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.